When: Daily close at or below $26.70 (50 SMA)

Then: Stop residual position at $26.70

TRIM 30-50% OF POSITION; reduce exposure to lock in gains while preserving upside optionality

• Price at $28.18, down 4% from $29.21 recent high; MACD still below signal line, no confirmed bullish setup
• Bounce volume of 32.6 million shares versus 75 million on selloff shows tentative rather than committed buyers
• Q2 2026 annualized FCF of $1.2 billion versus $9.8 billion annual dividend—most recent quarter is the leading indicator, not full-year 2025
• Pattern of escalating impairments: $5.86B in 2024, $9.16B in 2025, $4.3B in Q2 2026 alone
• Forward EPS consensus of $2.90 requires entire post-COVID rebuild to execute flawlessly; bear case requires only one disappointment to $2.40
• Eliquis and Ibrance represent $10-12 billion in revenue at risk—15-20% of total revenue facing patent cliffs in 2026-2027
• Polymarket data shows 96% probability of zero Fed cuts in 2026, removing multiple expansion as upside catalyst
• 23.9% run over twelve months has run into wall of negative catalysts; $2.90 estimate requires Seagen ramp, new products to offset exclusivity losses, manageable COVID decline, and no further impairments
• Trefis bull case derived from 'a smaller, faster part of the company'—structural admission legacy business is in decline
• Conservative recommendation: trim 30-50% to lock in gains from 24% year-to-date run and reduce exposure to known tail risk while maintaining upside optionality

→ vs aggressive: Technical bull flag argument ignores deteriorating tape: MACD below signal line, no volume confirmation at $29.09 resistance, chart 'doesn't know about the $4.3 billion impairment' or Eliquis biosimilar applications working through FDA

→ vs aggressive: Dividend coverage defense uses best data point (2025 FCF of $9.1B) while ignoring Q2 2026 annualized FCF of $1.2B—the most recent quarter is the leading indicator, not trailing twelve months

→ vs aggressive: ROE normalization thesis requires growth story to materialize; $2.90 consensus requires entire post-COVID rebuild to execute flawlessly, not just one or two positive outcomes

→ vs aggressive: Calling $9.7x forward P/E 'lazy analysis' for a 5% ROE business ignores that even crediting normalization leaves patent cliff execution risk unpriced

→ vs aggressive: Adding capital on retest of $27.50-$27.80 'is letting the technicals make the fundamental decision'—backwards approach when fundamentals show Q2 loss, weakening FCF, and looming patent cliff

→ vs aggressive: Seagen and pipeline framed as upside optionality are actually necessary offsets to known $10-12B revenue hole, not asymmetric upside sources

→ vs neutral: Hold at $28 means full downside exposure if dividend narrative cracks while giving up full upside if turnaround surprises—'gets hurt in both directions'

→ vs neutral: Q3 results will reveal whether Q2 $4.3B impairment was one-off or start of another round; waiting for confirmation is not a balanced position but rather exposure to binary catalyst

HOLD with 10-15% trim if portfolio rebalancing required; no new capital deployment; stop at 26.70; re-evaluation triggers at 29.09 (upside breakout) and 26.70 (downside breakdown)

• Technical setup is constructive: above 10 EMA, 50 SMA, and 200 SMA with all three sloping up
• RSI reset from 77 down to low 40s back to 60 represents a digestion pattern that often precedes the next leg higher
• MACD histogram contracting indicates bearish momentum from the nine-day pullback is dying
• Q2 free cash flow of $302M annualized is the leading indicator that cannot be dismissed as distortion
• Dividend coverage should be evaluated on forward earnings power normalized for charge cycle, not trailing TTM payout ratio of 800%
• Bull case requires 5 concurrent outcomes: Seagen $3B oncology revenue, Eliquis/Ibrance LOE defense through 2027, managed COVID decline, no further impairments, and $2.90 forward EPS within 10-15%
• The 24% gain captured argues for a smaller trim, not a maximum trim that locks in gains at the lower bound of the range
• 6.16% yield is a contested floor; dividend creates structural bid but is conditional on FCF stabilizing
• Close below 26.70 (50 SMA) breaks the technical foundation and invalidates the bullish thesis
• Breakout above 29.09 on volume above 40M shares with MACD bullish crossover above zero is the signal to lean bullish

→ vs aggressive: Q2 FCF of $302M annualized cannot be dismissed as distortion from working capital and tax timing — the most recent quarter's cash generation is the leading indicator

→ vs aggressive: The asymmetric upside framing is flawed; the bull case requires 5 separate things to go right simultaneously (Seagen integration, LOE defense, COVID decline management, no impairments, and EPS delivery), making it consensus-dependent on a story still in proof-of-concept phase

→ vs aggressive: Late-cycle defensive rotation thesis is overweighted; Polymarket data showing 96% probability of zero Fed cuts in 2026 means bond competition stays elevated, compressing the yield premium rather than rotating into a pharma name with a contested payout

→ vs conservative: Anchoring on trailing twelve month payout ratio of 800% is the wrong denominator — serious analysis uses forward earnings power normalized for the $19B cumulative impairment charge cycle

→ vs conservative: The proposed 30-50% trim ignores that technicals show buyers stepped in at the lower Bollinger Band; selling into a confirmed bounce off support in a structurally bullish trend contradicts the technical signal

→ vs conservative: Advocating for 30-50% trim while sounding bearish is inconsistent — if risk-reward is truly asymmetric to the downside, the logical position is a full exit, not a trim; the trim proposal reveals conviction isn't as strong as the rhetoric suggests